ORIGINAL RESEARCH article
Front. Med.
Sec. Translational Medicine
Efficacy and Safety of Tenofovir Amibufenamide in Patients with Chronic Hepatitis B: A Real-World Clinical Study
Rongshan Fan
Hongmei Fan
Linling Tan
Jun Zhang
Li Ai
Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Objective: To assess the real-world efficacy and safety of tenofovir amibufenamide (TMF) in patients with chronic hepatitis B (CHB) and to generate evidence to inform optimization of antiviral treatment selection in routine clinical practice. Methods: This study enrolled 186 patients with CHB, of whom 93 received TMF and 93 received tenofovir disoproxil fumarate (TDF) for 48 weeks. The primary endpoint was the virological response rate. Secondary endpoints included the rate of serum alanine aminotransferase (ALT) normalization; changes in hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels; and changes in renal and bone metabolism markers, including serum creatinine, uric acid, calcium, and phosphate. Results: After 48 weeks of treatment, virological response rates did not differ significantly between the TMF and TDF groups (P > 0.05). In contrast, the ALT normalization rate was significantly higher in the TMF group than in the TDF group (76.34% vs. 60.22%, P < 0.05). Similarly, the HBeAg seroconversion rate was markedly higher with TMF therapy (22.78% vs. 9.21%, P < 0.05). With respect to safety, serum creatinine levels at week 48 were significantly lower in the TMF group compared with the TDF group (77.36 ± 16.87 µmol/L vs. 90.12 ± 17.23 µmol/L, P < 0.05). No significant between-group differences were observed in serum uric acid, calcium, or phosphate levels. Conclusion: In real-world clinical practice, TMF is an effective treatment for CHB. Compared with TDF, TMF is associated with superior ALT normalization and higher HBeAg seroconversion rates, along with a more favorable renal safety profile.
Summary
Keywords
Chronic hepatitis B, efficacy, Real-world study, Safety, tenofovir amibufenamide
Received
13 January 2026
Accepted
17 February 2026
Copyright
© 2026 Fan, Fan, Tan, Zhang and Ai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rongshan Fan
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.